Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

• Revenue in USD (TTM)16.00m
• Net income in USD-297.06m
• Incorporated2005
• Employees112.00

• Location
  Syndax Pharmaceuticals Inc35 Gatehouse Drive, Building D, Floor 3WALTHAM 02451United StatesUSA
• Phone+1 (781) 419-1400
• Fax+1 (781) 419-1420
• Websitehttps://syndax.com/